Loading clinical trials...
Loading clinical trials...
To Determine the Effect of the Modified SQV/r (Saquinavir-boosted by Ritonavir) Regimen (500/100 mg for the 1st Week Followed by 1000/100 mg for the 2nd Week) on the QTc Interval, Pharmacokinetics, and Antiviral Activity in Treatment-naive HIV-1 Infected Patients
Conditions
Interventions
Nucleoside Reverse Transcriptase Inhibitor (NRTIs)
ritonavir
+1 more
Locations
1
United Kingdom
London, United Kingdom
Start Date
January 1, 2012
Primary Completion Date
June 1, 2012
Completion Date
June 1, 2012
Last Updated
November 2, 2016
NCT04142047
NCT06694805
NCT07428330
NCT07225530
NCT06665646
NCT05897099
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions